Precision Therapeutics, Inc. to Present Clinical Data Showing Significant Association between ChemoFx® Results and Improved Outcomes in Recurrent Ovarian Cancer at the 2013 European Cancer Congress
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Precision Therapeutics announced today that a recent clinical study supporting both the predictive and prognostic value of the ChemoFx® chemoresponse assay in recurrent ovarian cancer, has been accepted for poster presentation at the 2013 European Cancer Congress (ECCO-ESMO-ESTRO) to be held September 27 – October 1, 2013 in Amsterdam, Netherlands. The study, titled, Evaluation of a chemoresponse assay as both a prognostic and predictive marker in the treatment of persistent or recurrent ovarian cancer, will be presented as part of the “Diagnostics/Biomarkers” session of the biennial conference.
Help employers find you! Check out all the jobs and post your resume.
Precision Therapeutics announced today that a recent clinical study supporting both the predictive and prognostic value of the ChemoFx® chemoresponse assay in recurrent ovarian cancer, has been accepted for poster presentation at the 2013 European Cancer Congress (ECCO-ESMO-ESTRO) to be held September 27 – October 1, 2013 in Amsterdam, Netherlands. The study, titled, Evaluation of a chemoresponse assay as both a prognostic and predictive marker in the treatment of persistent or recurrent ovarian cancer, will be presented as part of the “Diagnostics/Biomarkers” session of the biennial conference.
Help employers find you! Check out all the jobs and post your resume.